Vaxil provides clarification and further information on the possible identification of a corona virus vaccine

Other new versions have been purposed with a unique form to accomplish cheap viagra generic the men’s requirement while treating ED. Side effects: From time to time patients taking Silagra experience the following side effects.Common Side Effects * Facial redness or flushing* Headache* Blocked nose* Dryness in eyes* Mild Nausea These common side effects of this medicine are found to be blocked nose, mild nausea, headache, blurriness in vision and so on but the serious side effects may result priapism, loss of vision or hearing senses which. generic levitra mastercard For men who smoke cigarettes, the ED can also be included in the therapy sessions, for muscle relaxation and for deeprootsmag.org generic cialis in canada quick muscle response in the rehabilitation process. VigRX Oil alone is online purchase of cialis sufficient to do the magic.

VAXIL BIO LTD., an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to provide further update to the Company’s press release dated February 13, 2020 on the possible identification of a corona virus (COVID-19) vaccine candidate (“Vaccine Candidate”).

The Vaccine Candidate is based on unique and patent protected signal peptide technology, utilizing Vaxil’s proprietary VaxHitTM bioinformatics platform. The Vaccine Candidate’s design is also based on successful in vivo experiments testing a tuberculosis signal peptide vaccine. Though significant, this is an early step in identifying a vaccine candidate which must then go through rigorous testing before approval by regulatory authorities.

During the next quarter, Vaxil plans to initiate non-GMP manufacturing. The non-GMP product will be made available for pre-clinical testing by those who express interest and qualify. In addition, Vaxil will explore partnerships and other possibilities to test the vaccine and if successful to bring to patients worldwide as expeditiously as possible

“This is a very early discovery and it is unlikely that there will be a prophylactic vaccine during this season, but we endeavor to have one for future use.” said David Goren, Vaxil’s Chairman and Chief Executive Officer.

[huge_it_slider id=”15″]Key Facts